CryoCor

CryoCor
Name	CryoCor
Type	Private
Founded	2002
Fate	Acquired (2011)
Headquarters	Redwood City, California
Industry	Medical devices
Products	Cryoablation systems
Key people	William J. Link, Venkata S. Venkataram, Peter J. Blank

CryoCor is a medical device company that developed percutaneous cryoablation systems for cardiac and other tissue ablation. The company operated in the Silicon Valley medical technology sector and pursued clinical indications in electrophysiology alongside competitors and collaborators in cardiovascular innovation. CryoCor's technologies intersected with interventional cardiology, electrophysiology, healthcare regulatory pathways, and device commercialization efforts involving multiple academic centers.

History

CryoCor was founded in 2002 amid a surge of medical device startups in Silicon Valley, aligning with venture investment trends involving firms like Sequoia Capital, Kleiner Perkins, and NEA. Early development drew on academic collaborations with institutions such as Stanford University, Johns Hopkins University, Cleveland Clinic, and Massachusetts General Hospital. The company sought FDA clearance pathways contemporaneously with other firms including Medtronic, Boston Scientific, St. Jude Medical, and Biotronik. Strategic milestones included clinical feasibility studies, investigational device exemptions interacting with the Food and Drug Administration, and eventual acquisition discussions influenced by firms like Johnson & Johnson, Becton Dickinson, and Abbott Laboratories. By 2011 CryoCor's assets and personnel had been subsumed as part of consolidation trends visible in mergers such as CareFusion acquisitions and the broader consolidation among device makers including Stryker Corporation and Zimmer Biomet.

Technology and Products

CryoCor developed percutaneous cryoablation catheters and console systems intended for controlled freezing of tissue. Technical features referenced cryogen delivery, thermodynamic control, and catheter design comparable to products from Medtronic's cryoablation lines, while research frameworks invoked engineering groups at MIT, Caltech, and Georgia Institute of Technology. Device engineering leveraged materials science insights from labs associated with Oak Ridge National Laboratory and Lawrence Berkeley National Laboratory, and computational modeling akin to projects at NASA research centers. The product suite addressed catheter steerability, tip thermocoupling, and console software integration similar to regulatory submissions by Atricure and AngioDynamics. Peripheral device interoperability considered standards championed by IEEE and clinical informatics practices linked to Epic Systems implementations.

Clinical Applications

CryoCor targeted cardiac arrhythmias, notably atrial fibrillation and atrial flutter, partnering with electrophysiology centers at Mayo Clinic, Mount Sinai Hospital (New York), UCSF Medical Center, and Baylor College of Medicine for human studies. Ablation procedures were situated within clinical pathways alongside therapies such as radiofrequency ablation popularized by teams at Cleveland Clinic and catheter technologies from St. Jude Medical. Trials referenced endpoints used in studies conducted by investigators affiliated with European Society of Cardiology, Heart Rhythm Society, and academic trials emanating from University of Pennsylvania and Columbia University. Noncardiac uses explored cryoablation for oncology indications with investigators at Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, and MD Anderson Cancer Center, paralleling work from Galil Medical and Covidien.

Regulatory and Safety Profile

CryoCor navigated premarket regulatory processes with the Food and Drug Administration and engaged institutional review boards at hospitals such as Brigham and Women's Hospital and University of Michigan Health System. Safety considerations involved adverse event monitoring frameworks used by sponsors in trials overseen by ClinicalTrials.gov registries and safety committees modeled after standards from International Organization for Standardization committees and American College of Cardiology guidelines. Device risk assessments referenced standards promulgated by ASTM International and reporting mechanisms aligned with practices used by European Medicines Agency for CE marking. Postmarket surveillance and quality systems paralleled those required under ISO 13485 and corporate compliance regimes used by companies like Boston Scientific.

Business and Corporate Affairs

CryoCor operated within venture-backed medical device ecosystems where fundraising rounds involved interactions with investors similar to Versant Ventures, OrbiMed Advisors, and Domain Associates. Corporate governance included boards with members from academic and industry backgrounds such as executives who later joined firms like Abbott Laboratories and Medtronic. Partnerships, licensing discussions, and eventual acquisition reflected patterns seen in transactions involving Covidien and Cordis Corporation. Intellectual property strategy paralleled practices at institutions including Stanford Technology Ventures and relied on patent portfolios examined by firms like Fish & Richardson and WilmerHale. Commercialization challenges mirrored market dynamics encountered by startups sold to conglomerates such as Ethicon and Stryker.

Research and Development

R&D efforts combined preclinical studies at laboratories affiliated with Harvard University, University of California, San Diego, and Yale University with translational programs involving National Institutes of Health grants and collaborations with the American Heart Association. Publications appeared in journals overseen by editorial boards akin to those of The Lancet, New England Journal of Medicine, Journal of the American College of Cardiology, and Circulation. Investigators connected with CryoCor contributed to conferences organized by Heart Rhythm Society, Transcatheter Cardiovascular Therapeutics, and European Society of Cardiology congresses. Technology evolution tracked toward integration with imaging modalities from Philips and Siemens Healthineers and ablation mapping systems similar to those produced by Biosense Webster.

Category:Medical device companies